Status:
UNKNOWN
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
Lead Sponsor:
Carolina Research Professionals, LLC
Collaborating Sponsors:
Bayer
Conditions:
Prostate Cancer Metastatic
Eligibility:
MALE
Brief Summary
This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone ...
Detailed Description
This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone i...
Eligibility Criteria
Inclusion
- Eligible subjects are adults over the age of 18 with mCRPC that completed the eRADicAte study. The living study subject or legally authorized representative must be able to understand and sign the written informed consent form.
Exclusion
- A living study subject or his legally authorized representative are not able to understand or willing to sign the written informed consent form.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03414437
Start Date
October 1 2017
End Date
October 1 2021
Last Update
March 19 2019
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chesapeake urology Research Associates
Towson, Maryland, United States, 21204
2
Urology Cancer Center and GU Research Network
Omaha, Nebraska, United States, 68130
3
Associated Medical Professionals
Syracuse, New York, United States, 13210
4
Oregon Urology Institute
Springfield, Oregon, United States, 97477